Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.28 Million EUR | -17.42% |
| 2022 | 19.71 Million EUR | -75.34% |
| 2021 | 79.94 Million EUR | 20.97% |
| 2020 | 66.08 Million EUR | -26.44% |
| 2019 | 89.83 Million EUR | -4.73% |
| 2018 | 94.29 Million EUR | 21.48% |
| 2017 | 77.62 Million EUR | -44.08% |
| 2016 | 138.8 Million EUR | -12.99% |
| 2015 | 159.52 Million EUR | 262.75% |
| 2014 | 43.97 Million EUR | 35.79% |
| 2013 | 32.38 Million EUR | 135.6% |
| 2012 | 13.74 Million EUR | 99.87% |
| 2011 | 6.87 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 12.84 Million EUR | 0.0% |
| 2023 FY | 16.28 Million EUR | -17.42% |
| 2023 Q4 | 16.28 Million EUR | 0.0% |
| 2023 Q2 | 12.17 Million EUR | 0.0% |
| 2022 Q1 | 69.21 Million EUR | -13.42% |
| 2022 Q4 | 19.71 Million EUR | 0.0% |
| 2022 FY | 19.71 Million EUR | -75.34% |
| 2022 Q2 | 63.14 Million EUR | -8.78% |
| 2021 Q4 | 79.94 Million EUR | 37.37% |
| 2021 Q2 | 62.68 Million EUR | 0.95% |
| 2021 Q1 | 62.1 Million EUR | -6.03% |
| 2021 FY | 79.94 Million EUR | 20.97% |
| 2021 Q3 | 58.19 Million EUR | -7.16% |
| 2020 Q4 | 66.08 Million EUR | 0.0% |
| 2020 Q2 | 75.76 Million EUR | 0.0% |
| 2020 FY | 66.08 Million EUR | -26.44% |
| 2019 Q4 | 89.83 Million EUR | 0.0% |
| 2019 Q2 | 81.35 Million EUR | 0.0% |
| 2019 FY | 89.83 Million EUR | -4.73% |
| 2018 Q4 | 94.29 Million EUR | 0.0% |
| 2018 FY | 94.29 Million EUR | 21.48% |
| 2018 Q2 | 109.05 Million EUR | 0.0% |
| 2017 FY | 77.62 Million EUR | -44.08% |
| 2017 Q2 | 120.29 Million EUR | 0.0% |
| 2017 Q4 | 77.62 Million EUR | 0.0% |
| 2016 FY | 138.8 Million EUR | -12.99% |
| 2016 Q4 | 138.8 Million EUR | 0.0% |
| 2016 Q2 | 139.99 Million EUR | 0.0% |
| 2015 FY | 159.52 Million EUR | 262.75% |
| 2015 Q2 | 183.29 Million EUR | 0.0% |
| 2015 Q4 | 159.52 Million EUR | 0.0% |
| 2014 FY | 43.97 Million EUR | 35.79% |
| 2014 Q2 | 51.8 Million EUR | 0.0% |
| 2014 Q4 | 43.97 Million EUR | 0.0% |
| 2013 Q4 | 32.38 Million EUR | 0.0% |
| 2013 Q2 | 15.04 Million EUR | 0.0% |
| 2013 FY | 32.38 Million EUR | 135.6% |
| 2012 Q4 | 13.74 Million EUR | 0.0% |
| 2012 FY | 13.74 Million EUR | 99.87% |
| 2011 FY | 6.87 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -10.687% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 95.022% |
| Adocia SA | 24.95 Million EUR | 34.757% |
| Aelis Farma SA | 26.28 Million EUR | 38.046% |
| Biophytis S.A. | 11.93 Million EUR | -36.411% |
| Advicenne S.A. | 12.4 Million EUR | -31.232% |
| genOway Société anonyme | 31.84 Million EUR | 48.867% |
| IntegraGen SA | 8 Million EUR | -103.516% |
| Medesis Pharma S.A. | 1.92 Million EUR | -745.232% |
| Neovacs S.A. | 47.53 Million EUR | 65.746% |
| NFL Biosciences SA | 3.97 Million EUR | -310.061% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -9.18% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -334.561% |
| Sensorion SA | 46.49 Million EUR | 64.98% |
| Theranexus Société Anonyme | 7.23 Million EUR | -124.96% |
| TME Pharma N.V. | 2.49 Million EUR | -553.633% |
| Valbiotis SA | 33.24 Million EUR | 51.029% |
| TheraVet SA | 7.53 Million EUR | -116.108% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 53.841% |
| argenx SE | 4.11 Billion EUR | 99.604% |
| BioSenic S.A. | 9.55 Million EUR | -70.332% |
| DBV Technologies S.A. | 165.65 Million USD | 90.171% |
| Galapagos NV | 4.35 Billion EUR | 99.626% |
| Genfit S.A. | 173.87 Million EUR | 90.636% |
| GeNeuro SA | 6.31 Million EUR | -157.916% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 65.852% |
| Innate Pharma S.A. | 184.19 Million EUR | 91.16% |
| Inventiva S.A. | 69.13 Million EUR | 76.45% |
| MaaT Pharma SA | 42.93 Million EUR | 62.074% |
| MedinCell S.A. | 36.94 Million EUR | 55.933% |
| Nanobiotix S.A. | 93.89 Million EUR | 82.66% |
| Onward Medical N.V. | 43.62 Million EUR | 62.681% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 84.769% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 80.12% |
| Oxurion NV | 6.55 Million EUR | -148.58% |
| Pharming Group N.V. | 426.33 Million EUR | 96.181% |
| Poxel S.A. | 4.82 Million EUR | -237.591% |
| GenSight Biologics S.A. | 9.08 Million EUR | -79.179% |
| Transgene SA | 45.21 Million EUR | 63.991% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.152% |
| UCB SA | 15.53 Billion EUR | 99.895% |
| Valneva SE | 469.39 Million EUR | 96.531% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 47.186% |